Galmed Pharmaceuticals Ltd. (GLMD) News
Filter GLMD News Items
GLMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GLMD News From Around the Web
Below are the latest news stories about GALMED PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate GLMD as an investment opportunity.
Galmed Pharmaceuticals: Q3 Earnings SnapshotRAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of $2.31 per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. |
Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology. |
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory indications announced today that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a critical metabolic signaling hub as well as an extended cash runway, it plans to broaden its drug development activities. |
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential. But they trade at low prices, typically under $5 per share. Penny stocks tend to be highly volatile, with the potential for rapid gains or losses. This requires careful research and risk management. Fortunately, some of the better-known penny stocks are covered by Wall Street analysts who give strong buy ratings. This is a positive indicator, as analysts close |
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC"). |
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis. The patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countrie |